Orphazyme A/S (ORPH) received a Notice of Allowance for its US patent application 16/879,198 titled "ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS" - PatentGrants
- Nasdaq rises after strong Microsoft forecast
- Alphabet (GOOGL) Tops EPS and Revenue Estimates But Shares Dip on YouTube and Cloud Miss, Analysts See Positive Risk/Reward Despite High Expectations
- Oil drops more than 1% as U.S. stockpiles rise sharply
- Microsoft (MSFT) Stock Gains on Strong FQ1 Results and Guidance, Analysts Raise Price Targets on Azure and Windows Outperformance
- Goldman Sachs Expects Coca-Cola (KO) Stock to Outperform Today After Strong Q3 Results
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Orphazyme A/S (NASDAQ: ORPH) has received a Notice of Allowance for its US patent application 16/879,198 titled "ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS" - PatentGrants
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genius Brands (GNUS) Announces Acquisition of WOW! Unlimited Media Inc.
- MP Materials (MP) Stock Falls for Second Day Following Short Report
- Tesla (TSLA) Adds to Recent Gain, Up Another 4.8%
Create E-mail Alert Related CategoriesCorporate News, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!